Bladder Cancer During the COVID-19 Pandemic: The Calm Before the Storm?

Sarkis, Julien; Samaha, Ramy; Kattan, Joseph; Sarkis, Pierre

doi:10.2144/fsoa-2020-0101

Cited by 7 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delaying or omitting surgery for muscle-invasive bladder cancer (MIBC) patients and choosing treatment options like RT and chemotherapy may be suboptimal. However, in the COVID-19 pandemic, this delay has been avoidable due to operating room closure and saturation of ICU beds ( Sarkis et al, 2020 ). Therefore, some recommendations were proposed for treating these patients using RT even by curative or palliative indication.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy based management during Covid-19 pandemic – A systematic review of presented consensus and guidelines

Siavashpour

Goharpey²,

Mobasheri

2021

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Treatment management of cancer patients in the radiation oncology departments during the current COVID-19 pandemic is challenging. A systematic review of published consensus/guidelines on the role of radiotherapy prioritization, suggested treatment protocols, and set up management was undertaken based on the PRISMA protocol and through PubMed/PMC, Scopus, Google Scholar, Web of Science databases until 01/20/2021. One hundred and sixty-eight publications or regional consensus were included. Summary of recommendations contained: (1) using hypo-fractionated (Hypo-F) regimens for therapeutic/palliative indications, (2) delaying radiotherapy for several weeks or until pandemic over, (3) omitting radiotherapy by replacement of alternative therapies or active surveillance, (4) applying safer patients' setup and preparation protocols, (5) developing telemedicine/telehealth service. To conclude, it is essential to carefully weigh the risk of exposure to COVID-19 infection and the benefit of treating cancer patients during the pandemic. Trying to have a global guideline facing this or any other probable crisis is crucial for health care service.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiotherapy based management during Covid-19 pandemic – A systematic review of presented consensus and guidelines

Siavashpour

Goharpey²,

Mobasheri

2021

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…Carcinoma in the epithelial lining of the urinary bladder has been increasing over the years (Sarkis et al 2020 ). Globally, 573,278 bladder cancer (BCa) cases and associated 212,536 deaths were reported in 2020 (Sung et al 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic potential clustered miRNAs in bladder cancer

et al. 2022

View full text Add to dashboard Cite

At specific genomic loci, miRNAs are in clusters and their association with copy number variations (CNVs) may exhibit abnormal expression in several cancers. Hence, the current study aims to understand the expression of miRNA clusters residing within CNVs and the regulation of their target genes in bladder cancer. To achieve this, we used extensive bioinformatics resources and performed an integrated analysis of recurrent CNVs, clustered miRNA expression, gene expression, and drug–gene interaction datasets. The study identified nine upregulated miRNA clusters that are residing on CNV gain regions and three miRNA clusters (hsa-mir-200c/mir-141, hsa-mir-216a/mir-217, and hsa-mir-15b/mir-16-2) are correlated with patient survival. These clustered miRNAs targeted 89 genes that were downregulated in bladder cancer. Moreover, network and gene enrichment analysis displayed 10 hub genes (CCND2, ETS1, FGF2, FN1, JAK2, JUN, KDR, NOTCH1, PTEN, and ZEB1) which have significant potential for diagnosis and prognosis of bladder cancer patients. Interestingly, hsa-mir-200c/mir-141 and hsa-mir-15b/mir-16-2 cluster candidates showed significant differences in their expression in stage-specific manner during cancer progression. Downregulation of NOTCH1 by hsa-mir-200c/mir-141 may also sensitize tumors to methotrexate thus suggesting potential chemotherapeutic options for bladder cancer subjects. To overcome some computational challenges and reduce the complexity in multistep big data analysis, we developed an automated pipeline called CmiRClustFinder v1.0 (https://github.com/msls-bioinfo/CmiRClustFinder_v1.0), which can perform integrated data analysis of 35 TCGA cancer types.

show abstract

“…The expected increase in bladder cancer in the next months is one aspect of COVID-19′s effect on worldwide public health. Delays in cancer diagnosis and treatment during the pandemic increase the likelihood that thousands of cases would go unrecognized and untreated, leading to an increase in untreated bladder cancer incidence in the months to come [ 62 ].…”

Section: Resultsmentioning

confidence: 99%

Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Background: The aim of this paper is to discuss the impact of COVID-19 on patients with urological malignancies (prostate cancer, bladder and upper tract urothelial cancer, kidney cancer, penile and testicular cancer) and to review the available recommendations reported in the literature. Methods: A review was performed, through the PubMed database, regarding available recommendations reported in the literature, to identify studies examining the impact of COVID-19 on treatment and clinical outcomes (including upstaging, recurrence, and mortality) for uro-oncological patients. Results: The COVID-19 pandemic dramatically changed the urological guidelines and patients’ access to screening programs and follow-up visits. Great efforts were undertaken to guarantee treatments to high-risk patients although follow up was not always possible due to recurrent surges, and patients with lower risk cancers had to wait for therapies. Conclusions: Physically and mentally, uro-oncological patients paid a heavy price during the COVID-19 pandemic. Long term data on the “costs” of clinical decisions made during the COVID-19 pandemic are still to be revealed and analyzed.

show abstract

Bladder Cancer During the COVID-19 Pandemic: The Calm Before the Storm?

Cited by 7 publications

References 18 publications

Radiotherapy based management during Covid-19 pandemic – A systematic review of presented consensus and guidelines

Radiotherapy based management during Covid-19 pandemic – A systematic review of presented consensus and guidelines

Diagnostic and prognostic potential clustered miRNAs in bladder cancer

Impact of COVID-19 on Uro-Oncological Patients: A Comprehensive Review of the Literature

Contact Info

Product

Resources

About